RD-162
RD-162
RD-162 (pronounced: /ɑːr diː wʌn sɪks tuː/) is a term used in the field of medicine and pharmacology. The etymology of the term is not well known, but it is often used in the context of drug development and clinical trials.
RD-162 is a nonsteroidal antiandrogen (NSAA) that was never marketed. It is a analog of enzalutamide and was developed by the same team. RD-162 is closely related to apalutamide, which is a derivative of it. Both RD-162 and apalutamide act as potent and selective antagonists of the androgen receptor (AR), similarly to enzalutamide.
Pronunciation
RD-162 is pronounced as /ɑːr diː wʌn sɪks tuː/.
Etymology
The etymology of RD-162 is not well known. It is a term used in the field of medicine and pharmacology, often in the context of drug development and clinical trials.
Related Terms
- Nonsteroidal antiandrogen (NSAA)
- Enzalutamide
- Apalutamide
- Androgen receptor (AR)
- Analog (chemistry)
- Drug development
- Clinical trials
External links
- Medical encyclopedia article on RD-162
- Wikipedia's article - RD-162
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski